Literature DB >> 15112361

Establishment of a P-glycoprotein substrate screening model and its preliminary application.

Yi Wang1, Jiang Cao, Su Zeng.   

Abstract

AIM: To establish a high P-glycoprotein (P-gp) expressing cell line as a model for studying drug absorption and distribution, and to explore the preliminary application of this screening model.
METHODS: A full-length MDR1 cDNA fragment in plasmid pMDRA1 was first subcloned into plasmid pET28a(+), then MDR1 cDNA was cut from the recombinant plasmid with double-digestion and ligated into the mammalian expression vector pcDNA3.1(+). The recombinant plasmid pcDNA3.1(+)/MDR1 was transfected into breast cancer cell line Bcap37 using the Superfect transfection reagent. Several stably transfected clones were obtained after selection with G418. Real-time fluorescent quantitative RT- PCR and Western blot methods were used to detect the expression of P-gp, and the cellular location of the expressed protein was determined by immunohistochemical staining. Drug sensitivity assay was used to evaluate the biological function of expressed P-gp. Concentration of quercetin in cells was determined by high-performance liquid chromatography (HPLC).
RESULTS: The recombinant plasmid was confirmed to be inserted in the correct orientation by restrictive enzyme digestion and DNA sequencing. Real-time fluorescent quantitative RT-PCR showed a higher level of P-gp mRNA in transfected cells compared to that in the control cells, and the Western blot result also indicated that P-gp expression in transfected cells was higher than that in control cells. The immunohistochemical staining showed that the expressed P-gp was localized on cell membranes. Drug sensitivity assay showed that the IC50 for adriamycin and colchicine of the transfected cells was higher than that of the control cells. The concentration of quercetin in model cells was lower than that in control cells by HPLC. After P-gp inhibitor verapamil was administered, the concentration of quercetin in model cells was increased.
CONCLUSION: A high P-gp expressing cell line can be established, which could provide a suitable in vitro model system for studying drug intestinal absorption mechanism, predicting the drug permeability characteristics and screening new multi-drug resistance reversing agents. With this model, quercetin can be found to be transported by P-gp, and it is a P-gp substrate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15112361      PMCID: PMC4622785          DOI: 10.3748/wjg.v10.i9.1365

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

Review 1.  Antioxidants in nutrition.

Authors:  S V Jovanovic; M G Simic
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 2.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

Authors:  S V Ambudkar; S Dey; C A Hrycyna; M Ramachandra; I Pastan; M M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

3.  Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.

Authors:  K Takara; Y Tanigawara; F Komada; K Nishiguchi; T Sakaeda; K Okumura
Journal:  Biol Pharm Bull       Date:  1999-12       Impact factor: 2.233

4.  Real-time quantitative polymerase chain reaction to assess gene transfer.

Authors:  K Becker; D Pan; C B Whitley
Journal:  Hum Gene Ther       Date:  1999-10-10       Impact factor: 5.695

Review 5.  The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens.

Authors:  H Wiseman
Journal:  Proc Nutr Soc       Date:  1999-02       Impact factor: 6.297

Review 6.  P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

Authors:  M Verschraagen; C H Koks; J H Schellens; J H Beijnen
Journal:  Pharmacol Res       Date:  1999-10       Impact factor: 7.658

7.  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Authors:  K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

Review 8.  Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.

Authors:  Jerome H Hochman; Masayo Yamazaki; Tomoyuki Ohe; Jiunn H Lin
Journal:  Curr Drug Metab       Date:  2002-06       Impact factor: 3.731

9.  A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro.

Authors:  Erin D Hugger; Barbara L Novak; Philip S Burton; Kenneth L Audus; Ronald T Borchardt
Journal:  J Pharm Sci       Date:  2002-09       Impact factor: 3.534

10.  Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells.

Authors:  R A Walgren; U K Walle; T Walle
Journal:  Biochem Pharmacol       Date:  1998-05-15       Impact factor: 5.858

View more
  1 in total

1.  Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin.

Authors:  Sylwia Borska; Miroslaw Sopel; Magdalena Chmielewska; Maciej Zabel; Piotr Dziegiel
Journal:  Molecules       Date:  2010-02-09       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.